Cancer remains a leading cause of global morbidity and mortality. Traditional therapies like chemotherapy and radiotherapy are often limited by their lack of specificity, leading to systemic toxicity and the emergence of drug resistance. Nanoparticles, with dimensions ranging from 1 to 100 nm, offer a sophisticated solution. Their unique physicochemical properties allow them to navigate biological barriers and can be engineered for active targeting (e.g., using ligands for overexpressed cancer cell receptors) or passive targeting (exploiting the Enhanced Permeability and Retention effect of tumor vasculature). The cellular uptake of these nanocarriers is a critical process, primarily occurring through various endocytic pathways such as clathrin-mediated, caveolin-mediated, and macropinocytosis, followed by crucial intracellular steps like endosomal or lysosomal escape to ensure the therapeutic cargo reaches its target intact.
Nanocarriers in Drug-Delivery Systems for Cancer Treatment
A diverse arsenal of nanocarriers has been developed, each with distinct advantages and limitations.
Liposomes, spherical phospholipid vesicles, were the first nanocarriers tested and are renowned for improving drug solubility and pharmacokinetics.
Solid Lipid Nanoparticles (SLNs) and related carriers provide good physical stability and controlled release.
Polymeric Nanoparticles (PNPs), derived from synthetic or natural polymers, offer high versatility for drug encapsulation and surface functionalization.
Dendrimers, highly branched macromolecules, are excellent for displaying multiple surface groups and encapsulating drugs within their internal cavities.
Inorganic Nanoparticles, including silica, carbon-based, and magnetic nanoparticles, offer unique properties such as high surface area, excellent conductivity, and responsiveness to external stimuli like magnetic fields. Many of these, particularly liposomal and polymeric formulations, have already gained regulatory approval for clinical use, underscoring their translational success.
Magnetic Hyperthermia: A Thermo-Therapeutic Revolution
Magnetic hyperthermia represents a revolutionary, minimally invasive approach. It involves the intratumoral delivery of magnetic nanoparticles (e.g., iron oxide) that generate localized heat when exposed to an alternating magnetic field (AMF). This heat (42–46°C) selectively disrupts cancer cells through protein denaturation, DNA damage, and induction of apoptosis, while sparing healthy tissues. Its true power, however, lies in its synergy; it can sensitize tumors to radiotherapy and chemotherapy, and magnetic nanoparticles can be co-loaded with drugs for triggered, thermally-activated release.
Viruses as Nanocarriers: Harnessing Nature's Design
Moving beyond synthetic systems, viral nanoparticles (VNPs) and virus-like particles (VLPs) leverage nature's efficiency. VNPs are derived from plant, bacterial, or mammalian viruses and may contain genetic material. VLPs, a subgroup of VNPs, are non-infectious as they lack the viral genome but retain the capsid structure. Their innate biocompatibility, precise structural organization, and natural tropism make them ideal platforms. They can be produced in expression systems like yeast, functionalized with targeting ligands, and loaded with drugs, genes, or imaging agents. VLP-based vaccines for HPV and Hepatitis B are a testament to their clinical viability.
Merging Strategies for Maximal Impact
The central highlight of this review is the powerful synergy achieved by combining these advanced technologies.
VLPs and Hyperthermia: VLPs can be engineered to encapsulate chemotherapeutics like doxorubicin and be decorated with targeting molecules (e.g., folic acid). When combined with magnetic hyperthermia, heat can trigger drug release from thermally-responsive VLPs directly within the tumor, enhancing specificity and efficacy.
Intranasal Delivery for Brain Tumors: The blood-brain barrier (BBB) is a major obstacle. Intranasal delivery bypasses the BBB by transporting drugs directly to the brain via the olfactory and trigeminal nerves. This route is being explored for delivering oncolytic viruses (replication-competent viruses that lyse cancer cells) and VLPs to treat aggressive brain tumors like glioblastoma.
VLPs Combined with Other Nanocarriers: To address inherent limitations of VLPs, such as limited payload capacity and physical instability, innovative hybrid systems are being developed. These include VLPs conjugated to gold nanoparticles for enhanced photothermal therapy, VLPs coated onto magnetic nanoparticles to improve dispersibility and targeting, and the use of biomimetic silica nanocages templated from VLPs to boost cellular uptake and biocompatibility.
Conclusions and Future Directions
The combination of cutting-edge strategies in nano-delivery presents a formidable, multi-pronged attack on malignant tumors. While synthetic nanoparticles have paved the way, the integration of VLPs and magnetic hyperthermia offers a new dimension of precision and power. The future of oncology therapy lies in these multimodal approaches that synergize targeting, controlled drug release, and immune activation. However, challenges in large-scale manufacturing, long-term toxicity, and precise clinical translation remain. Overcoming these hurdles through continued research will be crucial to fully realize the potential of these merged nanotechnologies and transform them from promising prospects into standard, life-saving therapies.
Full text
https://www.xiahepublishing.com/2572-5505/JERP-2025-00020
The study was recently published in the Journal of Exploratory Research in Pharmacology .
Journal of Exploratory Research in Pharmacology (JERP) publishes original innovative exploratory research articles, state-of-the-art reviews, editorials, short communications that focus on novel findings and the most recent advances in basic and clinical pharmacology, covering topics from drug research, drug development, clinical trials and application.
